Integral Health Asset Management, LLC Precision Biosciences Inc Transaction History

Integral Health Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$1.15 - $3.34 $402,499 - $1.17 Million	-350,000 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.96 - $7.76 $518,000 - $1.36 Million	175,000 Added 100.0%	350,000 $1.08 Million
Q4 2021 Feb 02, 2022	BUY	$7.4 - $11.66 $370,000 - $583,000	50,000 Added 40.0%	175,000 $1.3 Million
Q3 2021 Nov 12, 2021	SELL	$9.18 - $14.15 $459,000 - $707,500	-50,000 Reduced 28.57%	125,000 $1.44 Million
Q2 2021 Aug 30, 2021	SELL	$8.07 - $12.52 $1.41 Million - $2.19 Million	-175,000 Reduced 50.0%	175,000 $2.19 Million
Q2 2021 Aug 13, 2021	BUY	$8.07 - $12.52 $2.82 Million - $4.38 Million	350,000 New	350,000 $4.38 Million
Q1 2021 May 10, 2021	SELL	$8.57 - $15.79 $1.2 Million - $2.21 Million	-140,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$5.98 - $12.47 $956,800 - $2 Million	-160,000 Reduced 53.33%	140,000 $1.17 Million
Q3 2020 Nov 16, 2020	BUY	$4.65 - $8.73 $1.4 Million - $2.62 Million	300,000 New	300,000 $1.85 Million
Q1 2020 May 15, 2020	SELL	$5.05 - $15.01 $252,500 - $750,500	-50,000 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$6.32 - $19.66 $316,000 - $983,000	50,000 New	50,000 $695,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $526M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.